Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event
    Summit & Event ：
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
    Learn More>
    Wealth & Capital Management
    Insurance & Finance
    Healthcare & Pharma
    Retail & FMCG
    Travel & Transportation
  • Shine Speaker Bureau
    Shine Speaker Bureau：
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
    Learn More>
    The Leader Networks
    Advisor
    Think-Tank
  • Shine Advisor
    Shine Advisor：
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
    Learn More>
    Briefing
    Consensus
    Customized Research
  • Shine Event Service
    Shine Event Service：
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
    Learn More>
Guest Information
Sarah ZHANG
Sarah ZHANG
发布时间: 2020 - 11 - 26
点击次数: 0
Positions： VP, Global Issuer Services
Company： HKEx-Hong Kong Exchanges & Clearing Ltd.
个人简介：
Ms. Zhang joined the Listing Department of HKEx in 2011 and was responsible for processing applications for IPO listing application, and coordinating listing policy initiatives and developments.  Ms. Zhang internally transferred to Beijing Representative Office since August 2015. Her key focus is on market development introducing and promoting the HKEX IPO platform to corporates, investors and financial institutions in Mainland China.
查看详情>>
Arthur QIANG
Arthur QIANG
发布时间: 2020 - 11 - 26
点击次数: 0
Positions： Executive Director & Presiden
Company： Apricot Capital
个人简介：
Mr. Qiang Jing is currently the president of SinoMab BioScience Limited (3681. HK). From 2010 to 2017, Mr. Qiang served as a Managing Director and the Head of research in medicine and healthcare of the Research Department of China International Capital Corporation Limited (“CICC”). During his tenure at CICC, Mr. Qiang won the first place in Asiamoney for healthcare of Asia region in 2017, and the first place for healthcare of Mainland China and Hong Kong for four consecutive years from 2014 to 2017. From 2015 to 2016, he was ranked the top three in the Greater China by Institutional Investor. Mr. Qiang is a Chartered Financial Analyst (CFA) and a Certified Financial Risk Manager (FRM). Mr. Qiang had a further research of tumor biology at Harvard Medical School and majored in finance at Tsinghua University for his PhD; In 2010, he graduated from Fudan University with a Master's degree in finance and graduated from Shanghai Jiao Tong University in 2005 with a Bachelor's degree in pharmacy.
查看详情>>
Frank FAN
Frank FAN
发布时间: 2020 - 11 - 26
点击次数: 0
Positions： Co-Founder & CSO
Company： Legend Biotech
个人简介：
Dr. Fan is the co-founder of Legend Biotech and currently serves the company as the Chief Scientific Officer. Dr. Fan received his medical degree at Xi’an Jiaotong University in 1993 and worked as a surgical resident in the kidney Transplantation Centre of the university before he pursued his Ph.D. in applied immunology at Hiroshima University, Japan. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of the mechanism of human B cell tolerance. Dr. Fan has been published in numerous peer-reviewed academic journals, including an original article published in Nature Medicine which lead to a major revision in the clinical guidelines of pediatric organ transplantation. Dr. Fan’s scientific achievement paved the way by showing that small children can be safely transplanted with ABO blood group mismatched organs, and saved many lives of infant patients. Dr. Fan was awarded the“New Key Opinion Leader”award by The Transplantation Society in 2006. Dr. Fan founded Legend Biotech in 2015 and the company grew into a global leader in cancer immunotherapy in just 5 years. A bispecific BCMA-targeting CAR-T product Dr. Fan invented entered a global partnership with Janssen to co-develop the global markets. The product received breakthrough designation from the FDA and PRIME scheme from the EMA. Dr. Fan is now leading the world’s largest cell therapy R&D team and is devoted to inventing more innovative technologies for treating solid tumors and other diseases.
查看详情>>
James YAN
James YAN
发布时间: 2020 - 11 - 26
点击次数: 0
Positions： Chief Operating Officer, R&D
Company： Zai Lab
个人简介：
James Yan, Ph.D., has been our Chief Operating Officer, R&D since April 2020. Prior to this role, he was the Executive Vice President and Head of Pre-Clinical Development and Program & Portfolio Management. Prior to joining Zai Lab, Dr. Yan was the head of the Covance early development Shanghai site, where he was responsible for all aspects of the business. Between 2009 and 2012, Dr. Yan served as the head of drug safety evaluation and program management of Hutchison Medi-Pharma. Prior to Hutchison Medi-Pharma, Dr. Yan had significant experience at Pfizer in the United States. Over the course of his career, Dr. Yan was involved in many IND and NDA filings for multiple drug candidates and gained substantial experience working with regulatory agencies in several countries. Dr. Yan holds a Ph.D. from Peking Union Medical University and completed post-doctoral training at the University of Chicago’s Ben-May Institute for Cancer Research. He is a diplomat of the American Board of Toxicology (DABT), a council member of the China Society of Toxicology and a member of the Drug Toxicity and Drug Safety Evaluation Committee, a member of Pharmaceutical Toxicology Committee of China Pharmacology Society and vice chairman of Drug R&D Committee of China Pharmaceutical Innovation and Research Association (PhIRDA).
查看详情>>